Intervention Group for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease
TACAD - Behavioral
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The purpose of the proposed study is to preliminarily evaluate Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of patients living with Alzheimer's disease (TACAD) in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

11 Primary · 4 Secondary · Reporting Duration: Baseline, 1 months post intervention, 3 months post intervention

Month 3
Change in Acculturation Stress Scale (ASS) score from baseline
Change in Caregiver Activity Survey score from baseline
Change in Caregiver Assessment of Behavioral Skill Scale score from baseline
Change in EQ-5D-5L scale score from baseline
Change in Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score from baseline
Change in Lawton ADL/IADL Scale score from baseline
Change in Midlife Women's Symptom Index from baseline
Change in Multidimensional Caregiver Strain Index from baseline
Change in Neuropsychological Inventory Questionnaire score from baseline
Change in Pearlin Mastery, Loss, and Competence Scale score from baseline
Change in Perceived Stress Scale score from baseline
Change in Quality of Life Scale in Alzheimer's Disease score from baseline
Change in Revised Memory and Behavior Problem Checklist score from baseline
Change in Social Readjustment Rating Scale (SRRS) score from baseline
Change in Ways of Coping Scale score from baseline

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Active Control Group
1 of 2
Intervention Group
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Intervention Group · No Placebo Group · N/A

Intervention GroupExperimental Group · 2 Interventions: TACAD, Alzheimer's Association website · Intervention Types: Behavioral, Behavioral
Active Control Group
Behavioral
ActiveComparator Group · 1 Intervention: Alzheimer's Association website · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 months post intervention, 3 months post intervention

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,501 Previous Clinical Trials
2,677,496 Total Patients Enrolled
21 Trials studying Alzheimer Disease
1,967 Patients Enrolled for Alzheimer Disease
Eun-Ok Im, PhD, MPHPrincipal InvestigatorEmory University
2 Previous Clinical Trials
499 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a family member of a person with PLAD.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.